Spring 2024

It’s hard to be in medicine at the moment, and one day’s recognition is not enough. As your peer, I honor my fellow physicians today and every day.

In a paradigm with many options, once multiple sclerosis is confirmed as a patient’s diagnosis, physicians are left with 1 question: What do we choose for long-term treatment?

Transgender and gender-diverse patients have unique neurological considerations, but often, neurologists are unaware of the needs that are specific to this community.

Four neurologists treating patients with epilepsy share their experience in and out of the clinic tackling issues of access for their patients.

TOPAMAD will include 70 children with epileptic spasms who experienced hormonal therapy failure to determine whether modified Atkins diet or topiramate is a more effective treatment approach.

This complex waste clearance pathway within the CNS plays a crucial role in maintaining brain homeostasis, as a mechanism of protein waste removal alongside autophagy and protein aggregate ubiquitination.

A panel of experts MS specialists provided commentary on the clinical development of these therapies, some of the specific agents within the pipeline, and how to navigate potential safety concerns.

The dihydroergotamine product’s application was supported by phase 1 comparative pharmacokinetic and safety data, and the phase 3 ASCEND trial.

With the approval, eplontersen becomes the first approved treatment for patients with hereditary transthyretin-mediated amyloid polyneuropathy that can be self-administered via an autoinjector.

The clinical hold is in reference to safety concern observed in the phase 3 FENhance studies of patients with relapsing forms of multiple sclerosis.

In a recent post hoc analysis of the Study C021 trial, findings support the idea that early adjustments to concomitant antiseizure medications enhance the retention of cenobamate, an FDA-approved treatment for focal seizures.

Both pediatric and adult patients with tuberous sclerosis complex demonstrated significant reductions in TSC-associated seizures with no new safety concerns identified.

Givinostat, a HDAC inhibitor, was supported by data from the phase 3 EPIDYS study, a randomized, double-blind, placebo-controlled, multicenter trial.

At 40 weeks, there were no observed cases of ARIA-edema, and new microhemorrhages occurred predominantly in patients with pre-existing conditions.

Findings from the trial demonstrated rapid and sustained clinical response in patients with Alzhiemer disease agitation during the open-label treatment phase and did not show any new safety signals.